文献速递胸部技术与安全CTPET

免疫检查点抑制剂治疗肺癌的影像学表现

The radiological appearances of lung cancer treated with immunotherapy.
PubMed 文献 · Br J Radiol · 2022-12-19

本文综述了免疫检查点抑制剂(ICIs)治疗非小细胞肺癌(NSCLC)等恶性肿瘤后出现的不同影像学缓解模式,讨论了免疫相关不良事件(irAEs)的影像学表现,并介绍了代谢影像学的现状与未来展望以及影像组学在ICIs治疗患者中的应用。

要点

  • ICIs通过遮蔽肿瘤细胞表面免疫检查点、恢复宿主免疫系统识别肿瘤细胞的能力来触发抗肿瘤免疫反应。
  • 综述聚焦ICIs治疗后出现的不同影像学缓解模式,需在阅片时识别非典型缓解表现。
  • 需识别免疫相关不良事件(irAEs)的影像学表现,并了解代谢影像学与影像组学的应用前景。

核心结论

  • ICIs已对包括NSCLC在内的多种实体瘤和血液系统恶性肿瘤的治疗和预后产生有利影响;本综述聚焦ICIs治疗后的不同影像学缓解模式、irAEs影像表现、代谢影像学及影像组学的应用。

研究设计与样本

  • 综述,检索范围与纳入文献数原文未报告。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Therapy and prognosis of several solid and hematologic malignancies, including non-small cell lung cancer (NSCLC), have been favourably impacted by the introduction of immune checkpoint inhibitors (ICIs). Their mechanism of action relies on the principle that some cancers can evade immune surveillance by expressing surface inhibitor molecules, known as "immune checkpoints". ICIs aim to conceal tumoural checkpoints on the cell surface and reinvigorate the ability of the host immune system to recognize tumour cells, triggering an antitumoural immune response.In this review, we will focus on the imaging patterns of different responses occurring in patients treated by ICIs. We will also discuss imaging findings of immune-related adverse events (irAEs), along with current and future perspectives of metabolic imaging. Finally, we will explore the role of radiomics in the setting of ICI-treated patients.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Milanese G, Mazzaschi G, Ledda RE, et al. The radiological appearances of lung cancer treated with immunotherapy. Br J Radiol. 2022. PMID: 36367539. doi:10.1259/bjr.20210270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。